7 - Anticancer Hybrids

https://doi.org/10.1016/B978-0-08-101011-2.00007-6Get rights and content

Abstract

Despite considerable advances in cancer medicines in the past 20 years, the global burden of cancer remains substantial. Moreover, continued emergence of drug resistance and corresponding reduced efficacy ensures that new anticancer drugs will be needed in the near future. As one of the multifactorial diseases, it is widely accepted that cancer chemotherapy with hybrids that combine the pharmacophoric moieties of bioactive compounds might exhibit numerous advantages over those with a single target. In this chapter, we discuss the strategies and principles of anticancer hybrids to obtain possible synergistic or overadditive effects by showcasing recently published compounds with a focus on drug candidates that are currently under clinical trials.

References (0)

Cited by (0)

View full text